<DOC>
	<DOCNO>NCT01342926</DOCNO>
	<brief_summary>The purpose study determine safety efficacy GSK933776 treatment geographic atrophy secondary age-related macular degeneration .</brief_summary>
	<brief_title>Clinical Study Investigate Safety Efficacy GSK933776 Adult Patients With Geographic Atrophy Secondary Age-related Macular Degeneration</brief_title>
	<detailed_description>This Phase 2a proof concept study design evaluate safety efficacy GSK933776 treatment geographic atrophy secondary age-related macular degeneration . This placebo-controlled parallel-group study double mask .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Adult patient ≥55 year age inclusive Evidence AMD confirm presence least 1 druse ≥125 μm diameter Welldemarcated GA due AMD total area 1.917 mm2 measure study eye Bestcorrected visual acuity score ≥ 35 letter ( approximately 20/200 Snellen VA equivalent well ) study eye Additional eye disease study eye could compromise assessment bestcorrected visual acuity image posterior pole History CNV secondary AMD study eye Any previous treatment AMD study eye , approve investigational , exception dietary supplement Risk cerebrovascular disease , cerebral hemorrhage stroke History systemic autoimmune disease Use platelet antiaggregants anticoagulant ( aspirin 325 mg/day allowable , subject allergic intolerable aspirin , clopidogrel 75 mg/day allowable ) Use chronic corticosteroid Uncontrolled hypertension spite antihypertensive medication Renal hepatic insufficiency clinically significant anemia More moderate MRI white matter change</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>age-related macular degeneration</keyword>
	<keyword>geographic atrophy</keyword>
	<keyword>dry AMD</keyword>
</DOC>